IVVD vs REGN vs VRTX vs ALNY vs ABBV

For growth investors, Invivyd, Inc.

(IVVD) is the stronger pick with 110. 5% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Invivyd, Inc. (IVVD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 8x versus Alnylam Pharmaceuticals, Inc. at 121. 4x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 08x versus Vertex Pharmaceuticals Incorporated's 2. 78x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +128.

4%, compared to -96. 3% for Invivyd, Inc. (IVVD). Over 10 years, the gap is even starker: VRTX returned +391. 4% versus IVVD's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Invivyd, Inc. 's 2. 03β — meaning IVVD is approximately 1393% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Invivyd, Inc. (IVVD) carries a lower debt/equity ratio of 1% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Invivyd, Inc.

(IVVD) is pulling ahead at 110. 5% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -98. 2% for Invivyd, Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -104. 0% for IVVD. At the gross margin level — before operating expenses — IVVD leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 08x versus Vertex Pharmaceuticals Incorporated's 2. 78x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 13. 2x forward P/E versus 37. 7x for Alnylam Pharmaceuticals, Inc. — 24. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVVD: 1133. 8% to $9. 50.

In this comparison, ABBV (2.

9% yield), REGN (0. 6% yield) pay a dividend. IVVD, VRTX, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Invivyd, Inc. (IVVD) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, IVVD: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IVVD is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; VRTX is a mid-cap quality compounder stock; ALNY is a mid-cap high-growth stock; ABBV is a large-cap quality compounder stock. REGN, ABBV pay a dividend while IVVD, VRTX, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.